CN101809000A - 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 - Google Patents

具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 Download PDF

Info

Publication number
CN101809000A
CN101809000A CN200880001916A CN200880001916A CN101809000A CN 101809000 A CN101809000 A CN 101809000A CN 200880001916 A CN200880001916 A CN 200880001916A CN 200880001916 A CN200880001916 A CN 200880001916A CN 101809000 A CN101809000 A CN 101809000A
Authority
CN
China
Prior art keywords
compound
disease
phenyl
disorder
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880001916A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·M·朗厄
C·G·克鲁瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority claimed from PCT/EP2008/050181 external-priority patent/WO2008084057A1/en
Publication of CN101809000A publication Critical patent/CN101809000A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880001916A 2007-01-10 2008-01-09 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 Pending CN101809000A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07100323 2007-01-10
EP07100323.0 2007-01-10
PCT/EP2008/050181 WO2008084057A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
CN101809000A true CN101809000A (zh) 2010-08-18

Family

ID=38069361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880001916A Pending CN101809000A (zh) 2007-01-10 2008-01-09 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物

Country Status (6)

Country Link
CN (1) CN101809000A (pt)
AR (1) AR064765A1 (pt)
BR (1) BRPI0806452A2 (pt)
MX (1) MX2009007405A (pt)
SA (1) SA08280759B1 (pt)
TW (1) TW200845963A (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547263A (zh) * 2010-11-18 2014-01-29 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN109640990A (zh) * 2016-05-25 2019-04-16 田边三菱制药株式会社 用于治疗焦虑症的(2S)-1-[4-(3,4-二氯苯基)哌啶-1-基]-3-[2-(5-甲基-1,3,4-噁二唑-2-基)苯并[b]呋喃-4-基氧基]丙-2-醇或其代谢物
CN111655265A (zh) * 2017-11-28 2020-09-11 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
CN115052868A (zh) * 2020-02-06 2022-09-13 伦敦制药与研究公司 大麻素硫酸酯、及其盐和用途
US11766430B2 (en) 2018-09-04 2023-09-26 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547263A (zh) * 2010-11-18 2014-01-29 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN103547263B (zh) * 2010-11-18 2015-12-09 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN109640990A (zh) * 2016-05-25 2019-04-16 田边三菱制药株式会社 用于治疗焦虑症的(2S)-1-[4-(3,4-二氯苯基)哌啶-1-基]-3-[2-(5-甲基-1,3,4-噁二唑-2-基)苯并[b]呋喃-4-基氧基]丙-2-醇或其代谢物
CN111655265A (zh) * 2017-11-28 2020-09-11 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
CN111655265B (zh) * 2017-11-28 2024-05-10 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
US11766430B2 (en) 2018-09-04 2023-09-26 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain
CN115052868A (zh) * 2020-02-06 2022-09-13 伦敦制药与研究公司 大麻素硫酸酯、及其盐和用途

Also Published As

Publication number Publication date
AR064765A1 (es) 2009-04-22
SA08280759B1 (ar) 2011-05-04
BRPI0806452A2 (pt) 2011-09-06
TW200845963A (en) 2008-12-01
MX2009007405A (es) 2009-07-17

Similar Documents

Publication Publication Date Title
DE69127260T2 (de) Therapeutische heterocyclische verbindungen
DE60007329T2 (de) N-heterozyklische derivate als nos inhibitoren
CN101809000A (zh) 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物
JP2004520382A (ja) ムスカリン受容体アゴニスト
EP2091939B1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
US8138174B2 (en) Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
JP2019532076A (ja) 置換ヒドロキシスチルベン及びそれらの治療への応用
WO2007138050A1 (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
CA2527192C (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
WO1994013642A1 (de) Substituierte benzazepinone
FR2771093A1 (fr) Derives d'imidazole, leur preparation et leur application en therapeutique
EP0680960A1 (en) Imidazole compound
JPH04282374A (ja) 新規５ｈ−ベンゾジアゼピン誘導体、それを含有してなる製剤組成物、およびそれらの製造方法
CA2671554A1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
EP2029580B1 (de) Neue indol-pyrrol-derivate zur behandlung proliferativer und inflammatorischer krankheiten
WO2017022733A1 (ja) ピペラジン誘導体
US4985427A (en) Triazine derivatives
BRPI0721060A2 (pt) Composto, processo para preparar o composto, medicamento, composição farmacêutica, e, uso de um composto
TW200811143A (en) Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
AU2008263915A1 (en) 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
CN101939300A (zh) 作为大麻素cb1受体调节剂的4,5-二氢-(1h)-吡唑衍生物
PL166800B1 (pl) Sposób wytwarzania nowych pochodnych Indolu
JPH06271567A (ja) イミダゾール系化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1143362

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1143362

Country of ref document: HK